Congratulations to Rhythm Pharmaceuticals on its $120M Initial Public Offering

Read More

TANGO THERAPEUTICS APPOINTS BARBARA WEBER TO FULL-TIME CHIEF EXECUTIVE OFFICER

Read More

Congratulations to our Fierce 15 winners Magenta, Relay and Tango

Read More

Congratulations to Agios Pharmaceuticals for receiving FDA approval of IDHIFA for the treatment of acute myeloid leukemia

Read More

Congratulations to Kala Pharmaceuticals on its $90M Initial Public Offering

Read More

Third Rock launches Tango Therapeutics with $55M Series A to develop novel medicines designed to target cancer vulnerabilities

Read More

Third Rock announces Sarah Larson as Partner

Read More

Third Rock Launches Goldfinch Bio with $55M Series A to Develop Precision Therapies for Kidney Disease

Read More

Partner Abbie Celniker named among Boston Business Journal's 2017 Innovation All-stars

Read More

Third Rock launches Magenta Therapeutics with $48.5M to Apply New Stem Cell Science to Reboot the Immune System

Read More

Third Rock Ventures Raises $616 million Oversubscribed Fund

Read More

Sign up for weekly portfolio company news alerts here
 

Read More

Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock

Watch the Video

Partner Profile: Kevin Gillis

Read More

Transforming Healthcare

44

Portfolio Companies
With More Than $1.9 Billion
Under Management

45

Clinical Studies
Underway Within Our Portfolio

60

Diseases
Being Targeted By
Our Companies

10  

of thousands

Patients Impacted
By Portfolio Company Products
and Clinical Trials